These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 19100456

  • 1. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
    Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, Yamamoto J, Yokoyama H, Tomiya Y, Ishizawa K, Kameoka J, Harigae H.
    Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456
    [Abstract] [Full Text] [Related]

  • 2. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
    Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A, Yamane A, Ikeda Y, Okamoto S.
    Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201
    [Abstract] [Full Text] [Related]

  • 3. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M, Fujimori Y, Misawa M, Kai S, Nakajima T, Okikawa Y, Satake A, Itoi H, Takatsuka H, Itsukuma T, Nishioka K, Tamaki H, Ikegame K, Hara H, Ogawa H.
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [Abstract] [Full Text] [Related]

  • 4. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D, O'Toole K, Keller J, Connaghan DG, Heffner LT, Hillyer CD, Rodey GE, Winton EF, Maher RM, Fitzsimmons WE, Wingard JR.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [Abstract] [Full Text] [Related]

  • 5. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases.
    Miyakoshi S, Kami M, Tanimoto T, Yamaguchi T, Narimatsu H, Kusumi E, Matsumura T, Takagi S, Kato D, Kishi Y, Murashige N, Yuji K, Uchida N, Masuoka K, Wake A, Taniguchi S.
    Transplantation; 2007 Aug 15; 84(3):316-22. PubMed ID: 17700155
    [Abstract] [Full Text] [Related]

  • 6. [Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].
    Sun ZM, Liu HL, Geng LQ, Zhou CY, Wang XB, Ding KY, Tong J, Zhu WB, Liu X, Wang ZY.
    Zhonghua Yi Xue Za Zhi; 2012 Jun 26; 92(24):1660-4. PubMed ID: 22944153
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH.
    Biol Blood Marrow Transplant; 2004 May 26; 10(5):328-36. PubMed ID: 15111932
    [Abstract] [Full Text] [Related]

  • 8. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults.
    Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H, Hamaguchi M, Watanabe M, Kohno A, Murata M, Sawa M, Miyamura K, Morishita Y.
    Bone Marrow Transplant; 2007 Jan 26; 39(1):31-9. PubMed ID: 17115066
    [Abstract] [Full Text] [Related]

  • 9. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul 26; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 10. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
    Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn V.
    Bone Marrow Transplant; 2004 Sep 26; 34(5):425-31. PubMed ID: 15273705
    [Abstract] [Full Text] [Related]

  • 11. [Clinical study of double units unrelated cord blood transplantation in adult patients with hematological malignancies].
    Yin Y, Ren HY, Cen XN, Qiu ZX, Ou JP, Wang WS, Xu WL, Wang MJ, Wang LH, Li Y.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb 26; 29(2):73-7. PubMed ID: 18681304
    [Abstract] [Full Text] [Related]

  • 12. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov 26; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes of unrelated donor umbilical cord blood transplantation for 30 adults with hematological malignancies.
    Kobayashi K, Maeda Y, Hara Y, Nishie-Kataoka M, Nishimori H, Sugiyama H, Namba N, Kubonishi S, Niiya M, Shinagawa K, Ikeda K, Tanimoto M.
    Anticancer Res; 2009 May 26; 29(5):1763-70. PubMed ID: 19443401
    [Abstract] [Full Text] [Related]

  • 14. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP, Silver SM, Adams PT, Jacobson P, Scalzo A, Ratanatharathorn V.
    Bone Marrow Transplant; 1997 Jun 26; 19(12):1233-8. PubMed ID: 9208118
    [Abstract] [Full Text] [Related]

  • 15. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct 26; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

  • 16. Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies.
    Mori T, Tanaka M, Kobayashi T, Ohashi K, Fujisawa S, Yokota A, Fujita H, Nakaseko C, Sakura T, Nannya Y, Takahashi S, Kanamori H, Kanda Y, Sakamaki H, Okamoto S, Kanto Study Group for Cell Therapy.
    Biol Blood Marrow Transplant; 2013 Mar 26; 19(3):486-91. PubMed ID: 23253560
    [Abstract] [Full Text] [Related]

  • 17. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1997 Dec 26; 3(6):324-30. PubMed ID: 9502300
    [Abstract] [Full Text] [Related]

  • 18. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
    Tomonari A, Takahashi S, Ooi J, Nakaoka T, Takasugi K, Uchiyama M, Tsukada N, Konuma T, Iseki T, Tojo A, Asano S.
    Eur J Haematol; 2006 Jul 26; 77(1):46-50. PubMed ID: 16573743
    [Abstract] [Full Text] [Related]

  • 19. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.
    Mochizuki K, Kikuta A, Ito M, Sano H, Akaihata M, Kobayashi S, Ohto H, Hosoya M.
    Clin Transplant; 2011 Jul 26; 25(6):892-7. PubMed ID: 21070366
    [Abstract] [Full Text] [Related]

  • 20. Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age.
    Konuma T, Takahashi S, Ooi J, Tomonari A, Tsukada N, Kato S, Sato A, Monma F, Kasahara S, Nagamura-Inoue T, Uchimaru K, Iseki T, Tojo A, Yamaguchi T, Asano S.
    Ann Hematol; 2009 Jun 26; 88(6):581-8. PubMed ID: 19030858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.